Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

An efficient method to produce high yield analogs of Hemi-Phorboxazole A with anticancer and antifungal activities

Description:

Brief Description: A two-step, high yield, method for synthesizing naturally derived, Hemi-Phorboxazole A analogs

 

Technology:

 

Problem:

(+)-Phorboxazole A and B, extracted from the sponge Phorbas sp., display extraordinary anti-proliferative activity against National Cancer Institute’s (NCI) panel of 60 human tumor cell lines. Due to their complex structures, the reported syntheses of Phorboxazole A and B analogues consist of 100 total steps with an average yield of 4%. The limited availability of these compounds has precluded the evaluation of their biological activity. As such, there is a need for improved syntheses of these compounds, featuring fewer steps while providing higher yield and selectivity.

 

Solution:

Researchers in the Smith lab have developed a two-step, high yield (85%) method for preparing Hemi-Phorboxazole A from a known precursor. Two analogues of Hemi-Phorboxazole were designed and synthesized in this manner. One analogue exhibits anti-proliferation activities of human cancer cell lines HCT-116 (colon) and SPKB-3 (breast). Another analogue shows antifungal activity against Candida albicans.

 

Synthesis of completely synthetic (+)-hemi-phorboxazole A.  From Smith AB et al, 2009.

 

Advantages:

·         Efficient two-step method to synthesize complex and scarce molecules, compared to previously-reported syntheses having 100 steps

·         Improved synthetic yield (~85%) over other reported procedures (average 4%)

·         Less expensive process than other known procedures

 

Applications:

·         Antitumor activities for colon and breast cancer cell lines

·         Antifungal activity against Candida albicans

-----------------------------------------------------------------------------------------------------------------------------------------

Stage of Development:

·         In vitro testing in human cell lines

 

Intellectual Property:

USSN 8,957,097

 

Reference Media:

Smith AB et al.  Org. Lett., 2009, 11(16), p. 3766-3769.

Dalisay DS et al.  Org. Lett., 2009, 11(9), p. 1967-1970.

 

 

Desired Partnerships:

License

 

 

Download PDF

 


Patent Information:
For Information, Contact:
Joshua Jeanson
Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania
jeanson@upenn.edu
Inventors:
Amos Smith
Keywords: